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Abstract
Prostate cancer (PCa) is a heterogeneous trait for which several susceptibility loci have been implicated by genome-wide
linkage and association studies. The genomic region 13q14 is frequently deleted in tumour tissues of both sporadic and
familial PCa patients and is consequently recognised as a possible locus of tumour suppressor gene(s). Deletions of this
region have been found in many other cancers. Recently, we showed that homozygous carriers for the T442C variant of the
ARLTS1 gene (ADP-ribosylation factor-like tumour suppressor protein 1 or ARL11, located at 13q14) are associated with an
increased risk for both unselected and familial PCa. Furthermore, the variant T442C was observed in greater frequency
among malignant tissue samples, PCa cell lines and xenografts, supporting its role in PCa tumourigenesis. In this study, 84
PCa cases and 15 controls were analysed for ARLTS1 expression status in blood-derived RNA. A statistically significant
(p = 0.0037) decrease of ARLTS1 expression in PCa cases was detected. Regulation of ARLTS1 expression was analysed with
eQTL (expression quantitative trait loci) methods. Altogether fourteen significant cis-eQTLs affecting the ARLTS1 expression
level were found. In addition, epistatic interactions of ARLTS1 genomic variants with genes involved in immune system
processes were predicted with the MDR program. In conclusion, this study further supports the role of ARLTS1 as a tumour
suppressor gene and reveals that the expression is regulated through variants localised in regulatory regions.
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Introduction
Prostate cancer (PCa) is a heterogeneous trait, and it is the most
common malignancy among men in western countries, including
Finland. It is a multifactorial disease, and definitive risk factors
include age, ethnic origin and family history. In Finland, the
incidence of PCa is 89.4/100,000, and in 2010, 4697 new prostate
cancer cases were diagnosed (http://www.cancer.fi/
syoparekisteri/en/). Despite extensive research over the last
decade, the etiological risk factors and genes that cause genetic
susceptibility remain largely unknown. This lack of knowledge has
hampered effective cancer prevention and development of better
treatments.
Mutations in the known high-penetrance PCa predisposition
genes explain only a small fraction of PCa cases. A polygenic
model for familial aggregation of cancer has been proposed where
several low-penetrance alleles may have a multiplicative and/or
modifying effect. One low-penetrant candidate gene is ARLTS1
(ARL11), ADP-ribosylation factor like tumour suppressor protein
1, a putative tumour-suppressor gene on chromosome 13q14,
which has been shown to function in many human cancers [1–5].
ARLTS1 is a member of the ADP-ribosylation factor family that
plays a role in apoptotic signalling. The same chromosomal area
on 13q has been indicated in a multi-centre genome-wide linkage
study in families with at least five affected members [6]. In another
recent study, the immediate adjacent region 13q13 showed a
suggestive linkage to PCa, with a HLOD.1.9 [7]. In addition, the
locus 13q14 is among the most frequently deleted chromosomal
regions in somatic tumour tissues in both unselected and
hereditary prostate cancers [8,9], suggesting that ARLTS1 could
be a target for both germline and somatic mutations. We
previously reported a significant association of ARLTS1 T442C
(rs3803185) homozygote carriers with PCa [10]. This risk
genotype was also associated with decreased ARLTS1 expression
in the lymphoblastoid cell line samples of PCa patients, and
ARLTS1 co-expression signatures from data mining revealed that
ARLTS1 expression was strongly associated with immune system
processes. These processes are of interest because a link between
chronic inflammation and PCa progression has been repeatedly
proposed, and multiple genes acting in inflammatory pathways
have been linked to PCa susceptibility [11–13].
Complex diseases, such as cancer, are caused by a combination
of multiple genetic interactions and environmental factors, which
are hard to detect and link to each other. To determine true causal
associations using statistical methods and phenotype information,
it is advisable to organise individual markers into groups according
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e72040
to meaningful biological criteria, such as inflammation. By
composing variant sets, it is possible to reduce the number of
hypotheses being tested, which allows the association between a
genomic feature and a phenotype to be more easily detected.
Epistasis in genotype level is defined as the interaction among
multiple genes or loci, and this joint genetic effect may be the
factor behind ‘‘missing heritability’’, a phenomenon linked to the
unexplained portion of hereditary cancer susceptibility, which is
observed in PCa. The genome-wide expression quantitative trait
loci, eQTL, analysis is a method for studying epistasis in complex
traits that is able to detect associations between genotypic and
expression data. The eQTL analysis is a widely used approach to
gain insight into the role of single nucleotide polymorphisms
(SNPs) affecting transcript levels.
In this study, we investigated the mechanisms behind the
previously observed association of ARLTS1 and PCa by focusing
on finding gene/expression interactions that dispose patients to
PCa, including interactions involving the ARLTS1 gene. To
further investigate the ARLTS1 expression differences seen
previously in tumor samples, prostate cancer and lymphoblastoid
cell lines [10], we performed functional eQTL analysis from whole
blood derived total RNA from PCa patients. The previously
reported ARLTS1 co-expression with immune system processes
[10] was tested by MDR analysis. To our knowledge, this is the
first study reporting the findings of ARLTS1 interacting variants
and prostate cancer eQTLs at the 13q14 region.
Materials and Methods
Study population
All the samples were of Finnish origin. The identification and
collection of the Finnish HPC families has been described
elsewhere [14]. The familial samples analysed in this study had
at least two affected first or second degree relatives. Altogether,
102 prostate cancer cases and 33 healthy male family members
belonging to 31 families were initially taken into the study
population. The clinical characteristics of the familial patients used
in RNA sequencing (n = 84) are referred to in Table 1. Average
age at diagnosis was 63.0 y.
Patient information and samples were obtained with full written
informed consent. The study was performed under appropriate
research permissions from the Ethics Committees of the Tampere
University Hospital, Finland, as well as the Ministry of Social
Affairs and Health in Finland.
Genome-wide SNP Genotyping
Genome-wide SNP genotyping was performed using the
HumanOmniExpress BeadChip microarray (Illumina, Inc., San
Diego, CA, USA) by the Technology Centre, Institute for
Molecular Medicine Finland (FIMM), University of Helsinki.
This array covers more than 700,000 markers with an average
spacing of 4 kb across the entire genome.
DNA Sequencing
The ARLTS1 variant status of the PCa patients used in Illumina
genotyping was examined by direct sequencing. Sequencing was
performed in an Applied Biosystems 3130xl Genetic Analyzer (Life
Technologies Corporation, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Primers and PCR conditions used in
the mutation screening are available upon request.
RNA Extraction and sequencing
Total RNA was extracted from 84 PCa cases and 15 healthy
male relatives. All subjects belonged to the 31 Finnish HPC
families mentioned above. Total RNA was purified from whole
blood collected in PAXgeneH Blood RNA Tubes (PreAnalytiX
GmbH, Switzerland/Qiagen/BD) using the MagMAXTM for
Stabilized Blood Tubes RNA Isolation Kit (AmbionH/Life
Technologies, Carlsbad, CA, USA) and the PAXgene Blood
miRNA Kit (PreAnalytiX GmbH, Switzerland/Qiagen/BD). The
RNA quality was assessed using the Agilent 2100 Bioanalyzer and
the Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa
Clara, CA, USA).
Library preparation, target enrichment and massively parallel
paired-end sequencing of expressed transcripts was performed by
Beijing Genomics Institute (BGI Hong Kong Co., Ltd., Tai Po,
Hong Kong) using Illumina HiSeq2000 technology (Illumina Inc.,
San Diego, CA, USA).
eQTL analysis
To obtain ARLTS1 expression values, first, the reads from RNA
sequencing were aligned with tophat2 using hg19 as the reference
genome [15]. The raw read count for ARLTS1 was calculated
using HTseq, and read counts were transformed to normalised
expression values using DESeq (www-huber.embl.de/users/
anders/HTSeq/, [16]). The linear regression model implemented
in PLINK was used to detect transcript specific variants.
Associations in cis were delineated by a 1 Mb window upstream
or downstream of the ARLTS1 SNP rs9526582, as most of the cis-
eQTLs are located within or close to the gene of interest [17]. In
addition, we applied a new method based on probabilistic indices
to test for eQTL. The new method is a non-parametric directional
test (similar to the well-known Jonckheere-Terpstra test), imple-
mented in our R-Package GeneticTools that is available on the
Comprehensive R Archive Network (http://cran.r-project.org/
package =GeneticTools), and a package description is under
Table 1. Clinicopathologic findings at diagnosis of the PCa
patients used in RNA sequencing (n = 84).
n (%)
Age at diagnosis
,65 years 48 (57.1)
$65 years 35 (41.7)
Stage
T stage
T1 (clinically undetectable) 31 (36.9)
T2–T4 (clinically detectable) 48 (57.1)
M stage
M0 (no evidence of metastasis) 53 (63.1)
M1 (bone metastasis) 0 (0)
MX (bone metastasis cannot be
assessed)
27 (32.1)
PSA value
,20 ng/ml 60 (71.4)
$20 ng/ml 14 (16.7)
Grade
Gleason score
,7 44 (52.4)
7 10 (11.9)
.7 0 (0)
doi:10.1371/journal.pone.0072040.t001
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development (unpublished data). P-values were calculated using
permutation tests and were adjusted for multiple testing by
applying the Benjamini-Hochberg correction. We also calculated
for each test size a in [0,0.1] the ratio of the amount of expected
test rejections and the amount of observed rejections. The a for
which the ratio of these two values was maximal, we chose also as
an optimal test size.
Gene expression dataset
All microarray gene expression data on cell lines (n = 1445)
included in these analyses are publicly available via the Gene
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/,
accession numbers; GSE36133, GSE7127, GSE8332, GSE10843,
GSE10890, GSE12777, GSE15455, GSE18773, GSE20126,
GSE21654 and GSE24795) and GSK Cancer Cell Line Genomic
Profiling Data (https://cabig.nci.nih.gov/tools/
caArray_GSKdata) (2008) [18] (GlaxoSmithKline). The bulk of
the gene expression data was acquired from the Cancer Cell Line
Encyclopedia (CCLE) (GSE36133) [19]. We used samples from
the most recent and widely cited Affymetrix microarray platform,
HGU133_plus 2.0, to perform these analyses.
Gene expression data Normalisation
Gene expression data normalisation was performed from the
raw CEL files using the Aroma Affymetrix (Version 1.3.0) R
package (http://www.aroma-project.org) based on custom CDF
files (version 16) found at http://brainarray.mbni.med.umich.edu
[20]. We processed expression for 19,003 distinct genes. All
computations were performed in the R statistical environment,
employing the BioConductor suite of packages.
Co-expression analysis of ARLTS1. The co-expression
analysis method was described previously [10]. The meta cell line
data (n = 1445) originated from over 48 human anatomical parts.
A correlation value .0.30 and a p-value ,0.05 were used as
determinants for a statistically significant association. We per-
formed multiple test corrections using Benjamini Hochberg and
Bonferroni methods. We decided to use the Benjamini Hochberg
(BH) method for selecting significantly co-expressed genes because
it was moderately strict at calling a gene pair correlation a false
positive.
In silico functionality prediction
RegulomeDB (http://regulome.stanford.edu/) and HaploReg
(http://www.broadinstitute.org/mammals/haploreg/haploreg.
php) [21,22] databases were used to further elucidate the role of
eQTLs in gene regulation. RegulomeDB allows he features of
DNA and regulatory elements of non-coding regions to be
assessed, and HaploReg is a tool for developing mechanistic
hypotheses of the impact of candidate regulatory non-coding
variants on clinical phenotypes and normal variation.
MDR analysis
The multifactor dimensionality reduction (MDR) program is
publicly available from the internet (www.epistasis.org). We used
version 2.0_beta_8.4 to examine gene-gene interactions. MDR
detects interactions in relatively small sample sizes. MDR is a non-
parametric, model-free data mining approach constructive
induction algorithm that transforms the high-dimensional data
into one-dimensional variables by pooling genotypes into high and
low risk groups based on the ratio of cases to controls that have the
genotype in question [23]. MDR selects one genetic model (a one,
two, three or four stage locus) that most successfully predicts the
phenotype or disease status, e.g., cancer. Data are then divided
into ten equal parts to perform a 10-fold cross-validation. The
model creates a training set (9/10 of the data) and testing set (1/10
data) to evaluate the prediction ability. The procedure repeats this
protocol ten times and calculates the cross-validation consistency
(CVC). CVC depicts the number of times that particular model is
chosen as the best one of those ten intervals. From the MDR
results section, testing balanced accuracy (TBA) shows how many
instances are correctly classified. The ARLTS1 genotypes from 102
PCa cases and 33 controls were combined with the GWAS data of
700,000 SNPs.
Selection of genes and SNPs for MDR
The genes functioning in immune system processes and
inflammation pathways were selected from a previously published
comprehensive collection made by Loza MJ et al. [24] because
MDR is not able to run data sets of thousands of SNPs within
reasonable time limits. In short, the SNPs selected included those
involved in apoptosis, cytokine signalling, Toll-like receptor
signalling, leukocyte signalling, complement, adhesion and natural
killer cell signalling. We also ran MDR with a subset of genes
gathered from our previous ARLTS1 co-expression studies (e.g.,
twelve genes within B-cell receptor [BCR] signalling pathway).
The total amount of SNPs was 12,011 of which 4,764 were found
in our Illumina Human OmniExpress GWAS data.
Results
RNA expression
The ARLTS1 RNA expression levels were analysed from total
RNA of 84 PCa cases and 15 controls. A significant decrease of the
ARLTS1 expression level in PCa cases was detected (p= 0.0037,
Fig. 1). This is in concordance with our previous results from cell
line, benign prostatic hyperplasia (BPH) and tumour specimen
RNA expression data [10].
eQTL analysis
To identify possible cis-acting genetic variants associated with
ARLTS1 transcript levels, we performed an eQTL analysis within
a special area of the 13q14 region. By a linear regression model
(PLINK), we were able to detect 5 eSNPs affecting ARLTS1
expression (Table 2). When the calculation window was dimin-
ished from 1 Mb to 200 kb, only one SNP, rs7997377, remained.
With the directional test performed by the R-Package analysis
tool, 11 statistically significant eSNPs were found (Table 2), and
two were in concordance with the PLINK linear regression model
Figure 1. Relative ARLTS1 RNA expression from PCa patients
and healthy controls. Relative ARLTS1 RNA expression was deter-
mined by RNA sequencing analysis. Columns represent means of
individuals; bars represent SD.
doi:10.1371/journal.pone.0072040.g001
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results. For both test procedures a test size of 0.01 was chosen. The
eSNPs found by the directional test were located mainly in non-
coding regions (Table 2). The genomic locations of the eSNPs
found in the 13q14 region are visualised in Figure 2. Altogether,
468 genomic variants within the 1 Mb region originating from
ARLTS1 SNP rs9526582 were tested by a linear regression model
and directional test.
After adjusting for multiple testing, a FDR of 39% in the linear
model and approximately 32% in the directional test has to be
accepted to keep the significant test results from the marginal p-
values. For a more common FDR level of 10% one significant
eSNP from the directional test remained significant (rs9568354).
When we considered the ratio of expected and observed significant
tests, a maximum ratio for a = 0.011 in directional test was
identified. For that a approximately 2.5 times more significant test
results appeared than expected. Hence, we report also the above
mentioned non-adjusted p-values for a significance level 0.01.
With linear regression model, the amount of observed significant
tests matched the amount of expected test rejections under the null
hypothesis.
The association of the eSNP genotypes with the ARLTS1
expression level was calculated. A statistically significant correla-
tion was naturally observed between all the 14 SNPs and ARLTS1
transcript levels. The eSNP genotype - ARLTS1 expression
association box plots are depicted in Figure 3.
The functionality and possible transcriptional regulatory effect
of the 14 eSNPs within genes found by eQTL was evaluated using
ENCODE-data in the RegulomeDB and HaploReg databases.
Altogether nine of the fourteen eQTLs are reported in
RegulomeDB. The findings in the GM12878 lymphoblastoid cell
line are emphasized below because this cell line resembles the
tissue type from which the RNA sequencing data was retrieved.
The most substantial evidence for the regulation of ARLTS1 was
found for SNP rs2532975. Its regulatory role is supported by its
location in a regulatory active region. According to the Chip-Seq
data from the GM12878 cell line, rs2532975 resides in a BATF
(basic leucine zipper transcription factor) binding site. In addition,
using position weight matrix (PWM) matching, a CDC5 (cell cycle
serine/threonine-protein kinase) binding motif has been identified
that spans the genomic position of this variant. Furthermore, a
promyelocytic leukemia zinc finger (PLZF) motif is reported in
HaploReg. As reported by HaploReg, CDC5 binding efficiency
decreases while PLZF binding increases. Additionally, the
chromatin state in the region surrounding rs2532975 might adopt
weak enhancer characteristics. This prediction is further strength-
ened by the presence of two histone marks in this region,
H3k4me1 and H3k4me2, identified in the GM12878 cells.
Another possible candidate for ARLTS1 regulation is rs9562905.
In a Chip-Seq study, a POLA2 binding site was identified in a
human embryonic stem cell line, H1-hESC, in the region
surrounding rs9562905. HaploReg predicts active enhancer
characteristics in the chromatin surrounding rs9562905 in the
lymphoblastoid GM12878 cells, similar to rs2532975. This
interpretation is supported by the presence of two enhancer
Figure 2. Schematic diagram showing the genomic locations of eSNPs gathered by eQTL analysis in PCa patients. The gene symbols
are as follows: CYSLTR2 (cysteinyl leukotriene receptor 2), FNCD3A (fibronectin type III domain containing 3A), MLNR (motilin receptor), CDADC1
(cytidine and dCMP deaminase domain containing 1), CAB39L (calcium binding protein 39-like), SETDB2 (SET domain, bifurcated 2/CLLD8), PHF11 (PHD
finger protein 11/NY-REN-34 antigen), RCBTB1 (regulator of chromosome condensation [RCC1] and BTB [POZ] domain containing protein 1/CLLD7),
ARLTS1 (/ARL11, ADP-ribosylation factor-like 11), EBPL (emopamil binding protein-like), KPNA3 (karyopherin alpha 3, importin alpha 4), SPRYD7 (SPRY
domain containing 7/C13orf1, chromosome open reading frame 1), MIR3613 (microRNA 3613), TRIM13 (tripartite motif containing 13), KCNRG
(potassium channel regulator), MIR-15A and MIR16-1 (microRNA genes 15a and 16-1) and DLEU2 (deleted in lymphocytic leukemia 2).
doi:10.1371/journal.pone.0072040.g002
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associated histone marks, H3k4me1 and H3k4me2. In addition, a
FAIRE-sequencing study conducted for the GM12878 cells also
implies that this region is in an open chromatin state and is
therefore likely to have regulatory activity.
The variants rs1543513, rs7997737 and rs9568354 share
similar chromatin structural features in the GM12878 cells.
According to HaploReg, the chromatin state associates with the
weakly transcribed region. This prediction is confirmed by the
elongation of histone mark H3k36me3 in the surrounding regions
of the variants rs1543513, rs7997737 and rs9568354. According to
RegulomeDB, rs1543513 is located within the Irx3 and Irx6
motifs. However, in HaploReg, the presence of these motifs is not
reported. Similarly, the transcription factor binding motif of AIRE
(autoimmune regulator) is reported for rs1262781 in RegulomeDB
but not in HaploReg. A MZF1 (myeloid zinc finger 1) motif
surrounding rs7997737 is reported in both databases. HaploReg
reports a negative LOD score difference for rs7997737, which can
be interpreted as lowered binding efficiency of MZF. Compared to
the three variants mentioned above, rs9568232 shares similar
characteristics regarding its chromatin state. According to
HaploReg, this chromatin state is related to elongated transcrip-
tion.
The variants rs2075610 and rs1262774 are located within
regions most likely under the control of epigenetic regulation by
the polycomb-group proteins in the GM12878 cells. In addition,
DNase-Seq studies performed for several cell lines indicate an
open chromatin state surrounding rs2075610. However, two
repressed state chromatin histone marks, H3k27me3 and
H3k9me3, have also been identified. Variant rs1262774 is not
reported in the RegulomeDB.
The remaining variants are located in heterochromatin regions,
according to HaploReg. For rs7995192, rs2580189 and
rs1262781, this prediction is further confirmed by the presence
of H3k27me3. In addition, another repressive state associated
histone mark, namely H3k9me3, is present in the rs7995192 and
rs2580189 regions. Although there is evidence of repressed state
chromatin, RegulomeDB reports that transcription factor binding
motifs do in fact span the genomic positions of rs2580189 and
rs1262781.
Two motifs for XBP-1 (X-box binding protein 1) and ATF6
(activating transcription factor 6) span the region of rs1262781,
according to RegulomeDB. HaploReg confirms the presence of
XBP-1 and ATF6 motifs and an additional motif for SOX-17
(SRY [sex determining region Y] box 17). HaploReg reports lower
predicted binding efficiencies for XBP-1 and ATF6 and a slightly
increased binding efficiency for SOX-17.
RegulomeDB reports a ZNF143 (zinc finger protein 143) motif
in the region surrounding SNP rs2580189. However, HaploReg
does not report the presence of this motif. Taken together, the
results gathered from RegulomeDB and HaploReg indicate that
the ARLTS1 eQTLs are located within regulatory areas of the
13q14 region.
Co-expression analysis
The GeneSapiens mRNA expression database data, including
ARLTS1 expression, from 1445 cell lines (48 cancer subtypes) and
prostate cancer tumours was available for interaction studies.
Altogether 1381 genes with correlation value .0.30 and p-value
,0.05 was found to be positively correlating with the ARLTS1
gene. Using DAVID GO functional clustering, (http://david.abcc.
ncifcrf.gov/tools.jsp) [25,26] a strong association with nucleus and
zinc-finger protein processes was illustrated when all the genes
positively correlating with ARLTS1 expression (n= 36) in the PCa
cell line cohort were taken into account (with a more stringent
correlation value .0.50). The group of nuclear processes (nucleus,
intracellular organelles, transcription and DNA-binding) was
enriched when data of PCa cell lines was studied. The enrichment
score was 13.49 with a p-value 1.1E-32. The adjusted Benjamin
score was 5.1E-30, and the cluster of zinc-finger binding proteins
revealed a p-value of 9.0E-22. The same phenomenon was
Table 2. Chromosomal region 13q14 risk variants (eSNPs) associated with differential ARLTS1 expression.
SNP Gene Position Allele1 Allele2 P-value Adjusted P-value
Linear regression model
RS1886014 N/A 49321044 A G 0,007 0,369
RS7997737 SETDB2 50033188 G A 0,006 0,322
RS7337547 N/A 50443527 C A 0,008 0,384
RS7995192 N/A 50782599 G A 0,008 0,331
RS2532975 N/A 50945011 G A 0,005 0,322
Directional test
RS2075610 MLNR 49795705 G A 0,010 0,322
RS7997737 SETDB2 50033188 G A 0,008 0,322
RS1543513 SETDB2 50034684 A C 0,007 0,322
RS9568232 PHF11 50089844 A G 0,000 0,322
RS9562905 N/A 50210212 A C 0,008 0,322
RS9568354 SPRYD7 50487993 A G 0,002 0,000
RS2580189 N/A 50806640 A G 0,009 0,322
RS2532975 N/A 50945011 G A 0,001 0,322
RS1262781 N/A 51066171 A G 0,010 0,322
RS1262774 N/A 51068896 A G 0,006 0,322
RS17074618 N/A 51153475 A G 0,006 0,322
doi:10.1371/journal.pone.0072040.t002
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observed within the whole data of cell lines (meta cohort) with
genes showing a correlation value .0.30. ARLTS1 co-expression
genes (with correlation value .0.50) from the meta cell line data
revealed a category of immune system processes (B-/T-cell
activation, leukocyte/lymphocyte differentiation and activation),
with an enrichment score of 2.94 (p-value 5.57E-7, adjusted
Benjamin score 2.9E-5).
ARLTS1 co-expression data of genes negatively correlated to
ARLTS1 identified a strong gene ontology of glycoprotein and
plasma membrane protein genes in PCa cell lines (n = 2722,
correlation value,20.50, enrichment score 52.13, p-value 3.4E-
72 and 38.35, p-value 7.9E-32, respectively). Within the negatively
correlating genes, a cluster of immunoglobulin domain containing
proteins harboured an enrichment score of 12.23 with a p-value of
5.4E-24. The GO term ‘‘cytokine activity’’ revealed an enrich-
ment score of 10.43 with a p-value of 6.5E-10 within negatively
correlating genes. In addition to the result of ARLTS1 negatively
correlating genes, we also identified clusters of G-protein coupled
receptors and cell-cell signalling.
Top five positively and negatively ARLTS1 correlating genes in
cell line data are presented in Table 3 (upper panel). Additionally,
results of the ARLTS1 co-expression with genes (SETDB2, PHF11,
SPRYD7, MLNR) that harbored eSNPs are presented in the lower
part of the Table 3, from the co-expression analysis performed in
the meta cell line, prostate cell line data and prostate tumor data.
The expression of ARLTS1 was positively correlated with the
expression of SETBD2, in both the whole data of cell lines (meta
cell line cohort) (correlation value 0.64, p-value 0.000) and in the
Figure 3. Correlation of the different genotype groups of eSNPs to ARLTS1 RNA expression levels. A, rs2075610; B, rs7997737; C,
rs1543513; D, rs9568232; E, rs9568354; F, rs1886014; G, rs7337547; H, rs7995192; I, rs9562905; J, rs2580189; K, rs2532975; L, rs1262781; M, rs1262774
and N, rs17074618.
doi:10.1371/journal.pone.0072040.g003
Table 3. ARLTS1 Co-expression signatures from tumor specimens and cell lines.
Gene Correlation value P-value Samples (n) pval_corrected* pval_corrected#
Top five genes
Co-expression in meta cell line data
Positive correlation
BTK 0,69 0 2818 0 0
GPR18 0,66 0 2818 0 0
CXorf21 0,66 0 2818 0 0
P2RY8 0,66 0 2818 0 0
PIK3CG 0,65 0 2818 0 0
Negative correlation
NCKAP1 20,62 1,69E-295 2818 3,22E-291 7,70E-295
CDC42BPB 20,59 1,64E-263 2818 3,11E-259 7,43E-263
GIPC1 20,57 1,10E-239 2818 2,10E-235 5,01E-239
PTMS 20,53 2,68E-208 2818 5,09E-204 1,22E-207
KIAA0284 20,53 1,04E-203 2818 1,97E-199 4,71E-203
Genes harboring eSNPs
Co-expression in meta cell line data
MLNR 20,15 1,35E-16 2818 2,57E-12 2,96E-16
PHF11 0,44 0,000 2818 0,000 0,000
SETDB2 0,64 0,000 2818 0,000 0,000
SPRYD7 0,28 0,000 2818 0,000 0,000
Co-expression in PCa cell lines
MLNR 20,35 0,0352 36 1 0,081
PHF11 0,09 0,608 36 1 0,704
SETDB2 0,61 9,01E-05 36 1 0,001
SPRYD7 0,17 0,336 36 1 0,451
Co-expression in prostate tumor samples
MLNR 0,03 0,821 75 1 0,934
PHF11 20,07 0,576 75 1 0,806
SETDB2 20,07 0,547 75 1 0,788
SPRYD7 20,34 0,003 75 1 0,045
*Bonferroni correction.
#Benjamini Hohchberg multiple testing correction.
doi:10.1371/journal.pone.0072040.t003
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specific PCa cell lines (correlation value 0.61, p-value 0.00009)
(Table 3). Expression of the PHF11 gene was positively correlated
with ARLTS1 expression in the meta cell line data (correlation
value 0.44, p-value 0.000). Expression of MLNR and SPRYD7 was
negatively correlated with ARLTS1 expression. ARLTS1 and
MLNR had a correlation value of 20.35 (p-value 0.04) in PCa
cell lines, and ARLTS1 and SPRYD7 had a correlation value of
20.34 (p-value 0.003) in prostate tumour specimens (Table 3).
The strong negative correlation of ARLTS1 and SPRYD7
expression levels was also validated in our transcriptome data of
84 PCa cases and 15 controls.
MDR analysis
By direct sequencing, we were able to detect six ARLTS1
variants at the same amplicon from PCa patients included in the
Illumina genotyping (n = 135). All the variants were previously
known (rs117251022, rs3803186, rs147120792, rs3803185,
rs138452698 and G446A [Trp149Stop]). To elucidate the
genotypic ARLTS1 interactions we used multifactor dimensionality
reduction (MDR). Gene-gene interaction status between ARLTS1
and genes functioning in immune system processes within 102 PCa
cases and 33 controls was calculated, but we were not able to find
any statistically significant ARLTS1 interactions in this study
cohort (data not shown).
Discussion
ARLTS1 is a cancer-predisposing gene with proven tumour
suppressor properties. However, very little evidence on function,
especially on pathways, is currently available. In this study, we
were able to verify downregulated ARLTS1 expression in the
blood-derived RNA of PCa patient samples, demonstrating for the
first time the effect of germline alteration on ARLTS1 expression
levels. Tumour suppressor function of the ARLTS1 gene has been
previously proven by Calin GA et al., who found that transduction
of full-length ARLTS1 to A549 cells in Nu/Nu mice decreased
tumour growth when compared to empty vector [1]. The ability of
ARLTS1 to suppress tumour formation in preclinical models has
also been observed with ovarian [27] and lung cancer cells [28].
However, these results are based on somatic mutations in
cancerous cell lines, whereas our result reveals a novel expression
difference at the germline level, supporting the role of ARLTS1 as a
tumour suppressor gene. In the future, these types of findings
could be used to enable screening and detection of at-risk patients
even before clinical diagnoses.
We have previously genotyped ARLTS1 variants in prostate,
breast and colorectal cancer [29] and produced a prostate cancer
follow-up study [10]. In the first study [29], we reported a
statistically significant association with ARLTS1 variants T442C,
G194T and prostate cancer risk. However, after adjusting for
multiple testing, none of the results were significant. In the follow-
up study with larger sample size, we reported a statistically
significant association with T442C variant and prostate cancer risk
[10]. We reported also a decreased or lost ARLTS1 RNA or
protein expression in clinical prostate tumors, prostate cancer cell
lines and xenografts, supporting the role of ARLTS1 as a tumor
suppressor gene. Thus, there is no conflict between the previous
publications and this study that is confirming the tumor suppressor
role of ARLTS1.
Here, 14 eSNPs located at the 13q14 region were shown to
significantly influence ARLTS1 transcript levels in PCa patients.
The eQTL analysis was performed with two methods, a linear
model approach and a directional test. One advantage of our
directional test method over the commonly used linear model
approach is its robustness against outliers and the weaker model
assumptions. In the linear model approach, the expression values
of the different genotype groups are considered to follow the same
normal distribution up to a location shift parameter. If the location
shift parameter is not equal to zero, it generates a testing problem.
The directional test only assumes that the different expression
values follow certain distribution functions, so a testing problem
only occurs if the distributions of the genotype groups are
stochastically ordered.
Interestingly, 5 of the eSNPs are located within the protein-
coding genes SETDB2, PHF11, SPRYD7 and MLNR. Two eQTLs
were positioned in the SETDB2 (SET domain, bifurcated 2) gene,
also known as the CLLD8 (chronic lymphocytic leukemia deletion
region gene 8 protein) gene, which functions mainly in epigenetic
regulation [30]. The PHF11 gene, another hit for the eSNPs, is a
positive regulator of Th1-type cytokine gene expression through
nuclear factor kappa B, (NF-kB) [30,31]. The third eSNP gene,
SPRYD7, (SPRY domain containing 7/chromosome 13 open
reading frame 1 [C13or1]) also known as chronic lymphocytic
deletion region gene 6 protein, (CLLD6) [32], is proposed to have a
tumour suppressor function because it has been detected to be
downregulated in B-CLL patients [33]. The SPRY/B30.2 protein
domain occurs in a variety of cellular proteins, mediates protein-
protein interactions and negatively regulates cytokine activities
[34,35]. The fourth eSNP gene, MLNR/MTLR1, (G-protein-
coupled receptor 38, GPR38) is a member of the G-protein
coupled receptor 1 family and is identified as the motilin receptor
[36]. The found eSNPs were not affecting the expression of the
gene they resided in, suggesting the role of these eSNPs as specific
regulators targeting ARLTS1 expression. However, no explicit
conclusions about the actual causal interaction between these
variants and ARLTS1 can be made without further functional
validation. The eQTL result gathered in this study was from a
relatively small sample set in which analyses encompassed 1 Mb
up- and downstream of the ARLTS1 gene. Thus, further validation
in larger sample sets and genomic areas are warranted. However,
in our results, one eSNP remained significant even after
adjustments for multiple testing. Those adjustments are intricate
in the case of eQTL analysis and studies with small sample sizes
often suffer from a low detection rate after multiple testing
adjustment [37]. One possible strategy to deal with this is to accept
a relatively high FDR for the sake of later validation in a larger
population. Here, no potential candidate eSNPs were excluded
from further studies because the a with largest ratio between
observed and rejected tests was considered as optimal test size.
Lymphoblastoid cell lines (LCLs) are widely used in eQTL
studies because they are an easily accessible source of patient
samples of a single cell type. Particularly with prostate cancer, the
tumour specimens of multiple foci are hard to collect in large
amounts making it difficult to reliably detect disease-associated
traits. By using prostate cancer specimens, it is possible to find
tissue-specific genetic effects, but the use of lymphoblastoid cell
lines or whole blood of familial prostate cancer patients enables
one to detect the possible heritable germline differences which may
contribute to prostate cancer susceptibility. It has been argued that
SNP-transcript approaches using LCLs of small sample sets are
underpowered [38], but many studies have been able to find
overlapping eQTLs in cell lines and primary tissues [39–41]. Our
finding of the eSNP in the SPRYD7 gene was endorsed in the co-
expression data, in which the ARLTS1 expression levels were
significantly correlated with SPRYD7 expression, and in the
prostate tumour specimens (Table 3). Additionally, in the data
from the ENCODE consortium, the significance and usage of
LCLs are justified because the lymphoblastoid cell line (GM12878)
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is one of the three cell lines in the higher priority Tier 1 cohort
[42].
There may be a joint effect between the 13q14 genes. For
example, one larger transcript variant that consists of more than
one gene has been proposed with SETDB2 and PHF11 [30]. Very
little is known about the interactions in this area, particularly the
genomic collaborators of the ARLTS1 gene. A recent study
identified cellular retinoic acid binding protein 2 (CRABP2) and
phosphoglycerate mutase 1 (PGAM1) as novel ARLTS1-binding
proteins using the in-frame cDNA library technique [43]. These
proteins were not observed in the expression or genotype level of
our data, so further studies are needed to elucidate the actual
ARLTS1 interacting genes and proteins.
Considering the interactions between ARLTS1 and inflamma-
tion pathway genes, it was our hypothesis that ARLTS1 would
have interactions with inflammatory genes, as chronic inflamma-
tion has been proposed as a prostate cancer risk factor. With MDR
analysis, we aimed to investigate the previously observed ARLTS1
connection with immune system processes [10]. Another aim was
to test the hypothesis of genes functioning in inflammation
processes affecting prostate cancer risk. However, we failed to
substantiate our hypothesis, and statistically significant association
between ARLTS1 T442C SNP and the inflammatory/immune
system SNPs was not found within the 700,000 SNPs analysed.
For the analysis, we extracted distinct SNP groups from 4,764
markers found from our data of 700,000 variants in total. One
possible reason for the negative results may be the relatively
limited sample set of 135 cases and controls because we were not
able to generalise the results to the test data. We were also
concerned about overfitting the data with MDR.
Our previously found association between ARLTS1 T442C and
prostate cancer risk may be caused by the interaction network of
different SNPs in the 13q14 region. Variant T442C may be
included in a very rare haploblock, or there may still be a missing
variant because the region has been connected to other cancers in
addition to PCa.
In conclusion, in this study we have shown that the ARLTS1
expression level is influenced by changes in germline expression
levels and that the ARLTS1 gene is a quantitative trait locus for 14
eSNPs in the 13q14 region. Thus, our results indicate a more
complicated network of changes that increase PCa risk than
merely one genetic variant in ARLTS1.
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